US Life Sciences Surge with AI-Driven Diagnostics and Pharma Deals in 2026
• The US life sciences industry gained momentum in 2026 despite NIH cuts and trade threats, fueled by AI advancements and major pharma deals. • Karius's AI genomic tests for immunocompromised patients detect 50% more pathogens in one day, analyzing millions of DNA reads after testing over 100,000 cases. • Biotech winter ended, shifting focus to preventive health via AI, data, and precise therapeutics amid administration priorities.
Leer original · txbiomed.org





